BerGenBio Yönetim

Yönetim kriter kontrolleri 2/4

BerGenBio CEO'su Martin Olin, Sep2021 tarihinde atandı, in görev süresi 3.17 yıldır. in toplam yıllık tazminatı NOK 10.23M olup, şirket hissesi ve opsiyonları dahil olmak üzere 51.5% maaş ve 48.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.078% ine doğrudan sahiptir ve bu hisseler € 26.27K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 1.8 yıldır.

Anahtar bilgiler

Martin Olin

İcra Kurulu Başkanı

NOK 10.2m

Toplam tazminat

CEO maaş yüzdesi	51.5%
CEO görev süresi	3.2yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	1.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Martin Olin'un ücretlendirmesi BerGenBio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-NOK 152m
Jun 30 2024	n/a	n/a	-NOK 155m
Mar 31 2024	n/a	n/a	-NOK 155m
Dec 31 2023	NOK 10m	NOK 5m	-NOK 190m
Sep 30 2023	n/a	n/a	-NOK 226m
Jun 30 2023	n/a	n/a	-NOK 258m
Mar 31 2023	n/a	n/a	-NOK 293m
Dec 31 2022	NOK 11m	NOK 5m	-NOK 302m
Sep 30 2022	n/a	n/a	-NOK 294m
Jun 30 2022	n/a	n/a	-NOK 304m
Mar 31 2022	n/a	n/a	-NOK 309m
Dec 31 2021	NOK 4m	NOK 1m	-NOK 309m

Tazminat ve Piyasa: Martin 'nin toplam tazminatı ($USD 923.69K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 474.67K ).

Tazminat ve Kazançlar: Martin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Martin Olin (55 yo)

3.2yrs

Görev süresi

NOK 10,231,670

Tazminat

Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin Olin	Chief Executive Officer	3.2yrs	NOK 10.23m	0.078% € 26.3k
Rune Skeie	Chief Financial Officer	6.7yrs	NOK 3.59m	0.010% € 3.4k
Cristina Oliva	Chief Medical Officer	2.6yrs	NOK 5.70m	Veri yok
Graham Morell	Head of IR	no data	Veri yok	Veri yok
Gayle Mills	Chief Business Officer	3yrs	NOK 3.39m	Veri yok
Akil Jackson	Medical Director	no data	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 7BG0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sally Bennett	Independent Non-Executive Director	3.9yrs	NOK 358.00k	0.012% € 4.1k
John Heymach	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
David Colpman	Non-Executive Director	less than a year	Veri yok	Veri yok
Shu Kam Mok	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Debra Barker	Independent Non-Executive Director	5.7yrs	NOK 344.00k	0.012% € 4.0k
Anders Tullgren	Independent Chairman of the Board	2.8yrs	NOK 848.00k	0.055% € 18.7k
Enriqueta Font	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Solange Peters	Member Scientific Advisory Board	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7BG0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

BerGenBio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024

Martin Olin to Step Down from BerGenBio ASA as CEO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

High number of new and inexperienced directors

BerGenBio ASA Announces Board Appointments

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Recent updates

BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024

Martin Olin to Step Down from BerGenBio ASA as CEO

BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

New major risk - Share price stability

New major risk - Market cap size

New major risk - Financial position

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

BerGenBio ASA Provides Update on Clinical Development

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

High number of new and inexperienced directors

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

New 90-day low: €2.90

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

Revenue in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: €3.47

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

New 90-day high: €3.31

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India

Revenue in line with expectations

BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

New 90-day low: €2.52

BerGenBio ASA to Present Clinical Translational Data from the Ongoing Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio Presents Data on Anti-Axl Antibody Tilvestamab

BerGenBio Announces First Patient Dosed with Bemcentinib in Relapsed Malignant Pleural Mesothelioma Investigator Sponsored Phase IIa Study

Bergenbio ASA Receives Regulatory Approval from the India Regulatory Authority to Proceed with Phase II Clinical Trial to Assess the Efficacy and Safety of Bemcentinib

BerGenBio ASA Receives Approval from Norwegian Regional Ethics Committee for COVID-19 South Africa Trial

New 90-day low: €2.67

BerGenBio ASA to Report Q2, 2020 Results on Aug 18, 2020

First half earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş